Loading...
•
Dec 31, 2024
Madrigal Q4 2024 Earnings Report
Madrigal reported increased revenue driven by Rezdiffra despite a net loss for Q4 2024.
Key Takeaways
Madrigal Pharmaceuticals reported net revenue of $103.3 million for Q4 2024 driven by Rezdiffra sales. The company incurred a net loss of $59.4 million due to high operating expenses related to Rezdiffra's commercial launch. Cost of sales was reported at $3.4 million for the quarter.
Net revenue of $103.3 million driven by Rezdiffra sales.
Net loss of $59.4 million for Q4 2024.
Operating expenses of $170.3 million, mainly due to Rezdiffra's commercial launch.
Cost of sales reported at $3.4 million for the quarter.
Forward Guidance
Madrigal plans to expand its presence in the MASH market through Rezdiffra sales and anticipated European approval.
Positive Outlook
- Anticipated European approval for Rezdiffra in mid-2025.
- Potential launch in Germany as the first country in Europe.
- Continued positive data from the MAESTRO-NAFLD-1 trial.
- Strong market position for treating F2 to F4c MASH patients.
- Growing body of evidence supporting Rezdiffra's efficacy.
Challenges Ahead
- High operating expenses impacting profitability.
- Continued net losses reported despite revenue growth.
- Significant cost of sales incurred during the quarter.
- Ongoing R&D expenses for late-stage clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...